Phio Pharmaceuticals Corp. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on December 18, 2019, regarding events occurring on December 16, 2019. The Company is a Delaware corporation with its principal executive offices in Marlborough, Massachusetts, and its common stock trades on The Nasdaq Capital Market under the symbol "PHIO".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes and Events
On December 16, 2019, the Company received written notice from The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel granted its request for continued listing. This decision follows a hearing held on December 12, 2019, regarding the Company's prior non-compliance with the minimum $1.00 bid price requirement, which was first notified on November 12, 2019.
Guidance, Outlook, and Conditions
Continued listing on Nasdaq is conditional upon the Company meeting two specific deadlines:
- January 16, 2020: The Company must inform the Panel that it has obtained an affirmative shareholder vote to implement a reverse stock split.
- January 29, 2020: The Company must demonstrate compliance with the bid price requirement by evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
Management includes forward-looking statements noting there is no assurance that the Company will obtain the necessary shareholder vote or achieve the required closing bid price.
Investor Verification Checklist
- Verify whether the Company has secured an affirmative shareholder vote for a reverse stock split by January 16, 2020.
- Monitor the daily closing bid price of PHIO stock to ensure it meets the $1.00 threshold for ten consecutive trading days prior to January 29, 2020.
- Review subsequent filings for any updates on the Company's compliance status with Nasdaq listing standards.